Medartis Holding AGXSWX:MED +2.16%84 ROC (Joel Greenblatt) % is 11.41% as of Dec. 2025, which is 145% above its 10-year median of 4.66. GuruFocus rates XSWX:MED with a GF Score™ of 84/100 and a GF Value™ of CHF106.42 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Medartis Holding AG ranks better than 59.69% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Medartis Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 11.41%.
The historical rank and industry rank for Medartis Holding AG's ROC (Joel Greenblatt) % or its related term are showing as below:
XSWX:MED'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4.56 Med: 4.66 Max: 12.85
Current: 11.85
During the past 12 years, Medartis Holding AG's highest ROC (Joel Greenblatt) % was 12.85%. The lowest was -4.56%. And the median was 4.66%.
XSWX:MED's ROC (Joel Greenblatt) % is ranked better than 59.69% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 3.94
vs XSWX:MED: 11.85
Medartis Holding AG's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Medartis Holding AG (XSWX:MED) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Medartis Holding AG ROC (Joel Greenblatt) % Related Terms
Medartis Holding AG ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Medartis Holding AG's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MED vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Medartis Holding AG's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medartis Holding AG ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medartis Holding AG's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Medartis Holding AG's ROC (Joel Greenblatt) % falls into.
Medartis Holding AG ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 11.41% mean?
Medartis Holding AG (XSWX:MED) has a ROC (Joel Greenblatt) % of 11.41% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Medartis Holding AG and its competitors. This is 145% above median its historical median of 4.66. According to the industry distribution chart, Medartis Holding AG ranks #339 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 40.3%.
Is Medartis Holding AG's ROC (Joel Greenblatt) % too high?
Medartis Holding AG's current ROC (Joel Greenblatt) % of 11.41% is 145% above median its 10-year median of 4.66. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 3.94. Medartis Holding AG's value of 11.41% is 189.6% above this industry median. Based on the distribution chart, Medartis Holding AG ranks #339 out of 841 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medartis Holding AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medartis Holding AG's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medartis Holding AG ranks #339 out of 841 companies for ROC (Joel Greenblatt) %. This puts Medartis Holding AG in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 3.94. Medartis Holding AG's value of 11.41% is 189.6% above this benchmark. While the company's 10-year median is 4.66 vs. the industry median of 3.94, Medartis Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 3.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medartis Holding AG's current ROC (Joel Greenblatt) % of 11.41% is 189.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Medartis Holding AG and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 3.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medartis Holding AG's current ROC (Joel Greenblatt) % is 11.41%, which is 145% above median its own 10-year median of 4.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medartis Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Medartis Holding AG (XSWX:MED) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF106.42, compared to a current price of CHF85.30 — trading 19.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 11.41%, which is 145% above median its 10-year median of 4.66 and 189.6% above the Medical Devices & Instruments industry median of 3.94. Medartis Holding AG's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Medartis Holding AG (XSWX:MED), the current ROC (Joel Greenblatt) % is 11.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medartis Holding AG (XSWX:MED) Overvalued in 2026?
Based on GuruFocus' analysis, Medartis Holding AG stock appears to be undervalued.
The current stock price of CHF85.30 is trading 19.8% below its estimated GF Value™ of CHF106.42.
GuruFocus considers Medartis Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:MED:
ROC (Joel Greenblatt) %: 11.41% (145% above median its 10-year median of 4.66)
GF Value™: CHF106.42 vs. price of CHF85.30 (19.8% below fair value)
Industry Position: 189.6% above the Medical Devices & Instruments median (#339 of 841)
No single metric tells the full story. See the XSWX:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from Europe, Middle East and Africa (EMEA) and also has a presence in North America, Asia Pacific, and Latin America.
84GF Score
Get the complete analysis for XSWX:MED
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MED has been successfully added to your 
